ACC 2023: SGLT2i Use - Dos and Don'ts

ACC 2023 Conference Coverage

A. Armbruster

SURPASS 2: Tirzepatide Versus Once-Weekly Semaglutide

Juan Frias

Effects of Low Calorie and Alternative Sweeteners Across the Lifespa…

Keck School of Medicine of USC

M. Goran

The Differences Between the Products of GLP1's and GLP/GIPs

Susan Brian

Discussing Retatrutide: A GIP, GLP-1, and Glucagon Receptor Agonist

Susan Brian

Incretin-based Therapies in the Management of Obesity and its Comorb…

Michigan Medicine

A. Rothberg

Switch, Change, Rearrange: Diabetes Medication Transitions, De-presc…

Jennifer Rosselli

S. Twillmann

New Research: Side Effect of GLP1

Susan Brian

An Introduction to Tirzepatide for Weightloss

Susan Brian

Predictors of Poor Response to Semaglutide for Weight Management

Ploutarchos Tzoulis

Patients in Cardiometabolic Jeopardy: Evolving Strategies for Cardio…

MUSC Cardiology

D. Lloyd-Jones

Understanding the Phenomenon of 'Ozempic Face'

San Francisco Dermatological Society (SF Derm)

F. Kamangar

Etiology of Obesity

Beverly Tchang

Carbohydrate-Insulin Model: A Physiological Perspective on the Obesi…

The Texas Heart Institute

D. Ludwig

Ozempic, Zepbound, and More: Behavioral Interventions & Weight Loss …

Baystate Health

M. Gortakowski, K. Jobbins

Weight Loss and Pharmacologic Management of Obesity in 2024

Caroline Apovian

Pharmacologic Options for Managing Obesity in Patients with Heart Fa…

UCLA Health

V. Surampudi

Diabetes: Matters of the Heart

Scripps Health

M. Wilkinson

Diabetes Updates

Duke Health

T. Setji

Guideline Recommended Therapy in Patients With Diabetic Kidney Disea…

Heart in Diabetes (HiD)

M. R. Weir